tor levels in the striatum and nucleus accumbens of the rat, Mol. w17x
Brain Res. 11 1991. 161–166.
w2x G.R. Breese, A.A. Baumeister, T.J. McCown, S.G. Emerick, G.
Frye, K. Crotty, R.A. Mueller, Behavioral differences between w18x
neonatal and adult 6-hydroxydopamine-treated rats to dopamine
agonists: relevance to neurological symptoms in clinical syndromes
with reduced brain dopamine, J. Pharmacol. Exp. Ther. 231 1984.
343–354.
w3x G.R. Breese, G.R. Duncan, T.C. Napier, S.C. Bondy, L. Iorio, R.A. w19x
Mueller, 6-Hydroxydopamine treatments enhance behavioral re- sponses to intracerebral microinjection of D1- and D2-dopamine
agonists into the nucleus accumbens and striatum without changing
dopamine antagonist binding, J. Pharmacol. Exp. Ther. 240 1987.
167–176. w20x
w4x J.P. Bruno, E.M. Stricker, M.J. Zigmond, Rats given dopamine-de- pleting brain lesions as neonates are subsensitive to dopaminergic
antagonists as adults, Behav. Neurosci. 99 1985. 771–775. w21x
w5x E.M. Byrnes, B.J. Johnson, J.P. Bruno, D1- and D2-receptor mediation of motoric behavior in rats depleted of DA as neonates: effects
of age and size of depletion, Neurosci. Lett. 181 1994. 69–72.
w6x J.F. Chen, B. Weiss, Ontogenetic expression of D2 dopamine receptor mRNA in rat corpus striatum, Dev. Brain Res. 63 1991. w22x
95–104.
w7x R. Cowburn, D. Young, J. Luthman, Enhanced adenylate cyclase
activity in neonatally dopamine lesioned rats is related to increased w23x
Gs-protein coupling, Eur. J. Pharmacol. 207 1991. 271–274.
w8x K.M. Dewar, J.-J. Soghomonian, J.P. Bruno, L. Descarries, T.A.
Reader, Elevation of dopamine D2 but not D1 receptors in adult rat w24x
neostriatum after neonatal 6-hydroxydopamine denervation, Brain
Res. 536 1990. 287–296. w25x
w9x G.E. Duncan, G.R. Breese, H.E. Criswell, K.B. Johnson, U.B.
Schambra, R.A. Mueller, M.G. Caron, R.T. Fremeau, D1 dopamine
receptor binding and mRNA levels are not altered after neonatal w26x
6-hydroxydopamine treatment: evidence against dopamine-mediated
induction of D1 dopamine receptors during postnatal development,
J. Neurochem. 61 1993. 1255–1262. w27x
w10x G. Fishell, D. van der Kooy, Pattern formation in the striatum:
developmental changes in the distribution of striatonigral neurons, J.
Neurosci. 7 1987. 1969–1978.
w11x P.A. Frohna, B.S. Neal-Beliveau, J.N. Joyce, Neonatal 6-OHDA w28x
lesions lead to opposing changes in the levels of dopamine receptors
and their mRNAs, Neuroscience 68 1995. 505–518. w29x
w12x P.A. Frohna, B.S. Neal-Beliveau, J.N. Joyce, Delayed plasticity of
the mesolimbic dopamine system following neonatal 6-OHDA le- sions, Synapse 25 1997. 293–305.
w13x C.R. Gerfen, M. Herkenham, J. Thibault, The neostriatal mosaic: II.
Patch- and matrix-directed mesostriatal dopaminergic and non- w30x
dopaminergic systems, J. Neurosci. 7 1987. 3915–3934.
w14x C.R. Gerfen, T.M. Engber, L.C. Mahan, Z. Susel, T.N. Chase, F.J.
Monsma Jr., D.R. Sibley, D and D dopamine receptor-regulated w31x
12
gene expression of striatonigral and striatopallidal neurons, Science
250 1990. 1429–1432.
w15x R. Guennoun, B. Bloch, Ontogeny of D1 and DARPP-32 gene w32x
expression in the rat striatum: an in situ hybridization study, Mol.
Brain Res. 12 1992. 131–139.
J.N. Joyce, Differential response of striatal dopamine and muscarinic
cholinergic receptor subtypes to the loss of dopamine. I. Effects of
intranigral or intracerebroventricular 6-hydroxydopamine lesions of
the mesostriatal dopamine system, Exp. Neurol. 113 1991. 261–276.
